XLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA Snubs CHRS

Today's Daily Dose brings you news about Acceleron Pharma's disappointing renal cell carcinoma trial results; Aimmune's PALISDE progress; reverse stock split of CEL-SCI; the FDA rejection of Coherus' biosimilar candidate; promising trial results of GTX's drug candidate in postmenopausal women with stress urinary incontinence and Regulus' shrinking pipeline.

from RTT - Biotech http://ift.tt/2rV9XUL
via IFTTT